Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies

Research output: Contribution to journalReview articlepeer-review


Recent work in genetics has identified essential driver mutations in gliomas and has profoundly changed our understanding of tumorigenesis. New insights into the molecular basis of glioma has informed the development of therapies demonstrating considerable potential, including immunotherapeutic approaches such as peptide and dendritic cell vaccines against EGFRvIII. However, the selective targeting of one component of a dysregulated pathway may be inadequate for a durable clinical response, given the intratumoral heterogeneity of glioblastoma (GBM) and hypermutated profiles displayed by tumor recurrences. Immune checkpoint blockade with anti-cytotoxic T lymphocyte antigen-4 (CTLA) and anti-programmed cell death 1 (PD-1) have demonstrated encouraging results in clinical trials with other solid tumors, and recent data suggest that this type of therapy may be particularly useful for tumors with high mutational burdens. Although the survival for patients with GBM has remains grim, the use of immunotherapy may finally change patient outcomes.

Original languageEnglish (US)
Pages (from-to)373-383
Number of pages11
JournalJournal of neuro-oncology
Issue number3
StatePublished - Jul 23 2015


  • Glioblastoma
  • Glioma
  • IDH1
  • Immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies'. Together they form a unique fingerprint.

Cite this